What is CreoSalus?
Operating as a diversified life-sciences holding company, CreoSalus manages a sophisticated portfolio that spans pharmaceutical manufacturing, human medical device engineering, and fine chemical production. Through its specialized subsidiaries—Thorn BioScience, Occam Design, and Advanced ChemTech—the organization addresses critical needs in both veterinary and human health markets. Thorn BioScience, in particular, has gained industry recognition for its regulatory-approved ovulation management solutions, such as SucroMate Equine, while maintaining a pipeline for advanced porcine reproductive health products. This integrated business model allows CreoSalus to maintain high-value operations across the entire life-sciences value chain, from chemical synthesis to finished drug delivery systems.
How much funding has CreoSalus raised?
CreoSalus has raised a total of $2.1M across 2 funding rounds:
Debt
$1M
Debt
$1.1M
Debt (2020): $1M with participation from PPP
Debt (2021): $1.1M led by PPP
Key Investors in CreoSalus
PPP
Public-Private Partnership
What's next for CreoSalus?
With this major enterprise-level funding, CreoSalus is positioned to accelerate its research and development initiatives and scale its manufacturing capabilities. The strategic allocation of this capital will likely focus on expanding the commercial reach of its existing product lines while advancing the clinical development of its pipeline assets. As the company navigates the complexities of the life-sciences landscape, this financial support provides the necessary runway to enhance operational efficiencies and pursue long-term growth objectives in the global medical and chemical markets. Future milestones will likely center on regulatory advancements and the scaling of its proprietary medical device technologies.
See full CreoSalus company page
